Orthobiologics Market Expands to USD 9.4 Billion by 2033, Fueled by Sports Injury Treatments

Market Overview:

According to IMARC Group's latest research publication, "Orthobiologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033", The global orthobiologics market size reached USD 6.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How AI is Reshaping the Future of Orthobiologics Market

• AI tools are helping doctors make faster, more accurate diagnoses from medical images, with studies showing radiograph detection accuracy levels as high as 98%, boosting clinician confidence.
• Big players like Stryker, Zimmer Biomet, and Smith & Nephew are using AI-driven robotics and smart devices to personalize orthopedic surgeries, which leads to fewer complications and quicker recoveries for patients.
• The UK government, through its NHS AI Award, is investing £140 million to get AI technologies—including orthobiologic tools—to more hospitals, supporting tens of thousands of patients each year.
• Companies are teaming up with AI partners, like Modern Sports Medicine & Wellness with NeuralCure AI, to roll out rapid treatment simulations and personalized plans, making recovery more efficient for patients nationwide.
• AI is driving a surge in research: orthopedic science publications rose significantly after AI tools became mainstream, showing just how much innovation is speeding up in the field.

Get Your Free "Orthobiologics Market" Sample PDF Report Now!

Key Trends in the Orthobiologics Market

• Stem Cell Therapy Surge: People are excited about stem cell treatments for regenerating bones and joints. Clinical trials show strong results, with companies like Galapagos acquiring CellPoint to push innovative orthopedic solutions forward.
• Viscosupplementation Gains Traction: Patients prefer viscosupplementation for non-surgical osteoarthritis relief, holding a 42% market share. Hyaluronic acid injections improve mobility, and Bioventus’ DUROLANE launch meets this growing demand with proven safety.
• Minimally Invasive Options Rise: Less invasive procedures are cutting recovery times, with hospitals commanding 75% market share. Japan’s government reimbursements boost access, while robotic systems from companies like Stryker enhance precision in treatments.
• Sports Injuries Drive Demand: With 3.7 million sports injuries yearly, orthobiologics like PRP therapies are booming. US emergency rooms report 8.6 million visits, and Orthofix’s PEMF solutions aid faster recovery for active patients.
• Acquisitions Fuel Innovation: Big names like Smith+Nephew, acquiring CartiHeal, are enhancing knee repair offerings. Zimmer Biomet’s $155 million Embody deal strengthens soft tissue healing, driving competition and innovation in orthobiologics.

Growth Factors in the Orthobiologics Market

• Platelet-Rich Plasma (PRP) Popularity: PRP is a hit for boosting tissue repair, with 8.6 million US emergency visits for injuries driving demand. Companies like Arthrex are rolling out PRP kits to meet this need.
• Bone Morphogenetic Proteins (BMPs) Growth: BMPs are key for bone healing, with 60% of spinal fusion surgeries using them. Medtronic’s Infuse leads, supported by FDA approvals, making it a go-to for complex orthopedic cases.
• Government Support for Biologics: Government funding, like NIH grants, fuels orthobiologics research, with $500 million allocated annually. This backs BMP and stem cell advancements, helping firms like Stryker innovate for better patient outcomes.
• Stem Cell-Derived Growth Factors: Stem cell therapies are surging, with 25% of orthobiologic procedures using them. Galapagos’ CellPoint acquisition boosts production, offering new solutions for cartilage and bone regeneration in clinics.
• Industry Mergers Boost Innovation: Zimmer Biomet’s $155 million Embody deal enhances growth factor tech for soft tissue repair. Such acquisitions, alongside Smith+Nephew’s CartiHeal buy, are shaping a competitive orthobiologics market.

Unlock Exclusive Insights—Buy the Full Report with a Discount!

Leading Companies Operating in the Orthobiologics Industry:

• Arthrex Inc.
• Globus Medical Inc.
• Integra LifeSciences
• Johnson & Johnson
• Medline Industries Inc.
• Medtronic plc
• NuVasive Inc.
• Orthofix Medical Inc.
• Smith & Nephew plc
• Stryker Corporation
• Terumo Corporation
• Wright Medical Group N.V.
• Zimmer Biomet

Orthobiologics Market Report Segmentation:

By Product:

• Demineralized Bone Matrix
• Allograft
• Bone Morphogenetic Protein
• Viscosupplementation Products
• Synthetic Bone Substitutes
• Others

Viscosupplementation Products dominate the market due to their effectiveness in treating osteoarthritis, especially in the knee.

By Type:

• Knee
• Ankle
• Hip
• Wrist and Shoulder
• Spine
• Others

Knee holds the largest share of the industry, driven by the high incidence of degenerative conditions and injuries.

By Application:

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial and Dental Applications

Osteoarthritis and Degenerative Arthritis represent the leading market segment due to their widespread prevalence and impact on mobility.

By End User:

• Hospitals and Ambulatory Centers
• Research and Academic Institutes
• Dental Clinics and Facilities
• Orthopedic Clinics

Hospitals and Ambulatory Centers exhibit clear dominance in the market due to their comprehensive diagnostic and treatment capabilities.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads the market, accounting for the largest share of the orthobiologics market.

Recent News and Developments in Orthobiologics Market

• 2024: North America continues to lead the market with over 75% regional share, driven by technological innovation and increased adoption of regenerative medicine techniques like PRP and stem cells.
• 2024: Zimmer Biomet launched Velofuse Gel and Velofuse Putty, injectable spinal bone graft substitutes enhancing surgical outcomes and improving ease of use for spine procedures.
• 2025: Asia-Pacific marks fastest growth, fueled by rising orthopedic surgeries in China and India, supported by government healthcare investments and expanding local manufacturing capacities.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302